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Abstract 
In this study, biologically synthesized iron oxide nanoparticles, called magnetosomes, are made fully 
biocompatible by removing potentially toxic organic bacterial residues such as endotoxins at 
magnetosome mineral core surfaces and by coating such surface with poly-L-lysine, leading to 
magnetosomes-poly-L-lysine (M-PLL). M-PLL antitumor efficacy is compared with that of chemically 
synthesized iron oxide nanoparticles (IONPs) currently used for magnetic hyperthermia. M-PLL and 
IONPs are tested for the treatment of glioblastoma, a dreadful cancer, in which intratumor nanoparticle 
administration is clinically relevant, using a mouse allograft model of murine glioma (GL-261 cell line). A 
magnetic hyperthermia treatment protocol is proposed, in which 25 µg in iron of nanoparticles per mm3 
of tumor are administered and exposed to 11 to 15 magnetic sessions during which an alternating 
magnetic field of 198 kHz and 11 to 31 mT is applied for 30 minutes to attempt reaching temperatures 
of 43-46 °C. M-PLL are characterized by a larger specific absorption rate (SAR of 40 W/gFe compared to 
26 W/gFe for IONPs as measured during the first magnetic session), a lower strength of the applied 
magnetic field required for reaching a target temperature of 43-46 °C (11 to 27 mT compared with 22 
to 31 mT for IONPs), a lower number of mice re-administered (4 compared to 6 for IONPs), a longer 
residence time within tumours (5 days compared to 1 day for IONPs), and a less scattered distribution 
in the tumour. M-PLL lead to higher antitumor efficacy with full tumor disappearances achieved in 50% 
of mice compared to 20% for IONPs. This is ascribed to better ability of M-PLL, at equal iron 
concentrations, to maintain tumor temperatures at 43-46°C over a longer period of times. 
Key words: Glioblastoma, nanomedicine, magnetic hyperthermia, alternating magnetic field, magnetotactic 
bacteria, magnetosomes 
Introduction 
Due to their low toxicity, iron oxide 
nanoparticles, IONPs, have been developed for 
different applications in diagnosis, i.e. as contrast 
agents in magnetic resonance imaging, MRI, or in 
cancer treatment, using magnetic hyperthermia. In 
magnetic hyperthermia, magnetic nanoparticles are 
introduced to tumors and heated at 41-50 °C under 
the application of an alternating magnetic field (AMF) 
of 10-40 mT and 50-200 kHz, [1,2,3,4]. In such 
treatments, IONPs can be directly administered to 
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glioblastoma of patients and heated under AMF 
application leading to an increased survival of 7 
months compared with conventional treatments 
without inducing any major side effects, [5]. Other 
glioblastoma treatments, which currently use 
doxorubicin, temozolomide, lenalidomide oral 
administration, [6,7,8,9,10], lead to partial efficacy and 
often appear to be highly toxic, [11], necessitating the 
development of new treatments such as magnetic 
hyperthermia.  
In this paper, we introduce new iron oxide 
nanoparticles, synthesized by magnetotactic bacteria, 
called magnetosomes, which are believed to be more 
efficient than chemical nanoparticles for magnetic 
hyperthermia treatments and can also be used for 
diagnostic purposes, [12,13,14,15]. This is due to a 
series of advantages such as improved heating 
properties, a high level of crystallinity, a specific 
homogenous distribution due to a chain arrangement. 
We have previously shown that it is possible to 
completely eradicate MDA-MB231 tumors of average 
volumes 100 mm3 grown subcutaneously under the 
skin of mice by administering 1 mg of a suspension 
containing magnetosome chains at the centre of these 
tumors and by applying 3 times during 20 minutes an 
alternating magnetic field with a frequency of 183 
kHz and strength of 40 mT, [16]. However, these 
encouraging results require further improvements. 
Indeed, chains of magnetosomes, which are directly 
extracted from gram negative magnetotactic bacteria 
without further treatment, contain endotoxins at their 
surface, which must be removed for medical 
applications. Moreover, these nanoparticles are 
synthetized by and extracted from AMB-1 
magnetotactic bacteria, a strain of magnetotactic 
bacteria with a poor yield of magnetosome 
production of less than 200-400 µg of magnetosomes 
per litre of growth medium. It is necessary to improve 
this yield for medical applications, [17].  
The new magnetosome synthesis method 
proposed herein increases the magnetosome 
production yield by a factor of 150 by using the MSR-1 
instead of the AMB-1 strain, leading to the production 
of 120 mg of magnetosomes per litre of growth 
medium. Based on previous study, [5], it appears that 
0.5 g of magnetosomes per patient may be necessary 
to treat glioblastoma using magnetic hyperthermia. 
Following a further step of up-scaling in larger 
volumes, which seems feasible and relatively 
inexpensive, [18], our treatment may be used at a 
large scale. The new method also eradicates the 
problem of endotoxins. Following extraction of 
magnetosomes from MSR-1 magnetotactic bacteria, 
magnetosomes are first purified to remove most 
organic material, and then coated with poly-L-lysine, 
to lead a biocompatible and stable suspension of 
magnetosome minerals coated with poly-L-lysine 
designated M-PLL. Anti-tumor efficacy of M-PLL and 
IONPs are compared by administering suspensions 
containing 25 µg in iron per mm3 of tumor of M-PLL 
or IONPs at the centre of highly aggressive GL-261 
glioblastoma tumors with sizes of 50 to 150 mm3 
grown subcutaneously on immunocompetent C57BL6 
mice. Mice are then exposed to 11 to 15 magnetic 
sessions of 30 minutes during which an AMF 
operating at a frequency of 198 kHz and average 
strength regulated between 11 mT and 31 mT is 
applied to attempt maintaining intratumor 
temperature at 43-46 °C. These targeted temperatures 
are chosen since they lead to efficient magnetic 
hyperthermia treatment of various cancers (glioma, 
lymphoma, melanoma and carcinoma) without 
causing serious damage in healthy surrounding 
tissues, [19,20,21,22]. Comparison between M-PLL 
and IONPs efficacy is carried out, [23,24,25], by taking 
into consideration the strength of the magnetic field 
needed to reach an intratumor temperature of 43-46 
°C, the number of mice requiring a second 
nanoparticle administration to re-activate the 
treatment, nanoparticle and temperature intratumor 
distributions, the decrease in tumor volume following 
treatments, and the percentage of fully cured mice. 
Materials and Methods 
Culture of magnetotactic bacteria in 70l 
semi-automated fermenter 
Magnetospirillum gryphiswaldense strain 
MSR-1 (DSM6361) was purchased from Deutsche 
Sammlung von Mikro-organismen und Zellkulturen 
(Brunswick, Germany) and stored in small aliquots of 
1 mL at - 80 °C. Cells were grown at 29 °C on solid 
activated charcoal agar medium as previously 
described, [26] under microaerobic conditions during 
7 days. Several black-brown colonies were collected 
from the solid agar medium and amplified at 29 °C 
under stirring at 100 rpm in 10 L of a growth medium 
devoid of iron, [27]. Cells were then diluted in a 35 L 
fermentation medium also devoid of iron. Fermen-
tation was carried out at 29-30 °C under agitation at 
200 rpm during 5 days with pH maintained at 6.9 by 
adding an acidic feeding medium containing 
FeCl3.6H2O as the iron source. Growth of 
magnetotactic bacteria was stimulated by bubbling 
oxygen in the growth medium at a percentage kept 
below 0.1 % to enable magnetosome synthesis, 
[28,29,30]. Temperature, agitation speed, pH, feeding 
pump flow and oxygen concentration were monitored 
and adjusted using an EZ controller and a BioXpert 
software from Applikon Biotechnology. 
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Purification of uncoated magnetosome 
minerals 
Following fermentation, MSR-1 cells were 
washed and concentrated in water using tangential 
flow filtration to an OD565 ~ 100. To lyse the bacteria, 
approximately 100 mL of concentrate MSR-1 cells 
were re-suspended in 400 mL of 1M NaOH and 
heated to 60 °C for 2 hours in 500 mL glass bottles 
placed in a sonicating bath at 25 kHz. A direct current 
field was then applied to the suspension overnight to 
separate magnetosomes from organic material 
residues. After separation, magnetosomes were 
re-suspended successively in: first, 500 mL of 1x PBS 
and sonicated at 10 W for 20 seconds, second 80 mL of 
1% Triton X-100 and 1% SDS heated at 50 °C 
overnight, third 80 mL of phenol at pH 8 heated at 60 
°C during 2 hours in the sonicating bath, fourth 80 mL 
of chloroform heated at 60 °C during 2 hours, and fifth 
80 mL of 1 M NaOH solution heated at 60 °C for 1 
hour in the sonicating bath. Between each step 1 to 5, 
magnetosome minerals were isolated from 
non-magnetic organic debris using a Neodymium 
magnet for 20 minutes. The supernatant was then 
removed and replaced by the next detergent or 
nonpyrogenic water after the fifth step. The resulting 
magnetosome minerals were autoclaved and stored at 
-80°C.  
Coating of magnetosome minerals with 
poly-L-lysine 
Uncoated magnetosome minerals were coated 
with PLL under sterile conditions. A suspension of 
PLL of 40 mg/ml (Gmac, CAS: 25988-63-0; molecular 
weight 21000 g/mol) mixed in pyrogen-free water 
was prepared, filtered with a polyethersulfone filter of 
0.45 µm and stored at -80 °C. For the coating, seven 
times more PLL than magnetosome minerals in 
weight were used. A suspension containing 25 mL of 
magnetosome minerals (iron concentration of 3 
mg/ml) was exposed to a 1.3 T magnetic field of a 
Neodymium magnet, the supernatant was replaced 
by 25 ml of PLL and the resulting suspension was 
introduced into a tube sonicated for 6 minutes at 4 °C 
using a 10 W sonicating finger. The tube was then 
shaken for 24 hours at 25 °C on a wheel, at a speed of 
13 rpm and the suspension was sonicated again with a 
10 W sonicating finger for 10 seconds at a temperature 
of 4-8 °C. Washing was carried out 1-4 times by 
placing the tube against the magnet, and by replacing 
the supernatant with sterile MilliQ water. The final 
suspension was sonicated for 2 minutes at 24 W on 
ice, holding the temperature below 4 °C to avoid 
heating, and the pH was adjusted to 6.8-7.2 with 
filtered KOH. We obtained a suspension of 
magnetosome minerals coated with PLL, herein 
referred to as M-PLL. 
Preparation and characterization of IONPs  
IONPs were purchased from Micromod 
Partikeltechnologie GmbH company, Germany (ref: 
10-00-102). IONPs are starch coated iron oxide 
nanoparticles, which have previously been 
successfully used preclinically in the magnetic 
hyperthermia treatment of tumor [31,32,33]. 
Characterization 
The sizes and shapes of magnetosomes inside 
MSR-1 bacteria, magnetosome minerals, M-PLL and 
IONPs were observed using a transmission electron 
microscope (JEM-2100, JEOL, Japan). The iron 
concentration of the different suspensions containing 
magnetosome minerals, M-PLL or IONPs, were 
determined by a colorimetric test: nanoparticles were 
mixed with hydrochloric acid and hydrogen peroxide 
to produce Fe3+ ions complexed with potassium 
thiocyanate, and total iron was then determined by 
measuring the absorbance at 476 nm with a 
spectrophotometer (UviLine9400, SECOMAM, 
France). Zeta potential of the different nanoparticles 
in suspension was measured by Dynamic light 
scattering, DLS (ZEN 3600, Malvern Instruments, 
UK). The stability of these suspensions was 
determined by measuring variation of the optical 
density at 476 nm during 15 min with a 
spectrophotometer (UviLine9400, SECOMAM, 
France). Nanoparticle FTIR spectra were recorded 
with a FTIR spectrometer (Vertex 70, Bruker, USA). 
The amount of organic material at nanoparticle 
surface was measured using an elemental CHNS 
analyser (Flash EA 1112, Thermo Fisher Scientific, 
USA). Hysteresis loops of the different nanoparticles 
were measured at room temperature between -1 and 
+1 T using a vibrating sample magnetometer (VSM 
3900, Princeton Measurements Corporation, USA). A 
Magnetic Properties Measurement System (MPMS 
XL-5, Quantum Design, USA) was used for saturating 
isothermal remanent magnetization (SIRM) 
measurements. More details about each of these 
techniques are provided in the supplementary 
material section.  
Ethics statement 
The in vivo study protocol was approved by the 
local animal ethics committee of the University 
Pierre-et-Marie-Curie (Paris, France). 
Hyperthermia treatments 
The GL-261 mouse glioma cell line (ATCC, USA) 
was cultivated in RPMI 1640 medium (GE Healthcare 
HyClone™, USA), supplemented with 10 % FBS at 37 
°C in humidified atmosphere containing 5 % CO2. 
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About 107 cells in 100 µL RPMI with 0,1 % BSA 
(Bovine Serum Albumine) were administered 
subcutaneously in the backs of 6 weeks old female 
C57/BL6 mice (n=60, M1-M60, ref: SC-CJ-SS-F, 
Janvier Labs, France), anesthetized with isoflurane. 
Ten days after tumor cell implantation when tumours 
have reached sizes of 50 to 150 mm3, mice were 
randomly separated into 6 groups (n=10 each) and 
treatment was started at day (D) 0, according to the 
protocols below. Experimental details are given in the 
supplementary material, tables S1 and S2. Briefly, 
• Group 1 (M1 to M10) received M-PLL, followed 
by a series of 11 to 15 magnetic sessions (MS) at 
day (D) 0, D2, D4, D7, D9, D11, D14, D16, D18, 
D21, D23, D25, D28, D30, and D32. The applied 
alternating magnetic field (AMF) had a 
frequency of 198 kHz and a strength ranging 
from 11 to 27 mT during first MS and from 11 to 
27 during subsequent MS. 
• Group 2 (M11 to M20) received M-PLL without 
subsequent AMF application. 
• Group 3 (M21 to M30) received IONPs, followed 
by a series of 7 to 15 MS at D0, D2, D4, D7, D9, 
D11, D14, D16, D18, D21, D23, D25, D28, D30, at 
D32. The applied AMF had a frequency of 198 
Hz and a strength ranging from 22 to 31 mT 
during first MS and from 22 to 27 during 
subsequent MS. 
• Group 4 (M31 to M40) received IONPs without 
subsequent AMF application. 
In groups 1 to 4, M-PLL or IONPs were always 
administered at tumor centre at a quantity of 25 µg in 
iron per mm3 of tumor (25 to 75 µL of nanoparticle 
suspensions at concentrations of 50 mg in iron per 
mL). 
In groups 1 and 3, MS duration was always 30 
minutes and the targeted intratumor temperature was 
43-46°C. For the first MS, the targeted intratumor 
temperature was always reached while for 
subsequent MS it was not always the case, and the 
AMF was then set to a maximum strength of 27 mT. 
For mice in which tumor volumes exceeded 150% of 
initial tumor sizes and targeted temperature of 43-46 
°C was not reached with a magnetic field frequency of 
198 kHz and strength of 27 mT, a second intratumor 
nanoparticle administration at 25 µg in iron of 
nanoparticles per mm3 of tumor was carried out.  
• Group 5 (M41 to M50) received an intratumor 
administration of 50 µl of 5% glucose followed 
by a series of 4 to 10 MS at D0, D2, D4, D7, D9, 
D11, D14, D16, D18, D21. During each MS, an 
AMF of frequency 198 kHz and average strength 
27 mT was applied. 
• Group 6 (M51 to M60) received an intratumor 
administration of 50 µl of a suspension 
containing 5 % glucose. 
Groups 2, 4, 5, and 6 are considered as control 
groups, i.e. groups of mice without nanoparticle 
administration and/or AMF applications. 
Tumour volumes (TV), expressed in mm3, were 
measured with a calliper and estimated using the 
formula TV = 0.5.L.W2, where L and W are the largest 
and smallest tumor dimensions respectively, [34, 35]. 
Tumor volumes, mouse weight and mouse behaviour 
were either monitored or measured at D0, D2, D4, D7, 
D9, D11, D14, D16, D18, D21, D23, D25, D28, D30, 
D32. Mice were euthanized when tumor volumes 
exceeded 1000 mm3 and/or when mice weight has 
decreased by more than 20 % from one measurement 
to the next one. Mouse survival curves were recorded 
during a 250 day period following first MS (D0).  
Temperature monitoring and distribution 
During each MS, intratumor temperature was 
first measured locally at the site of nanoparticle 
administration using an optical fibre (Fluoroptic 
Temperature Probe, LumaSense Technologies, 
France) placed in the central part of the tumour. 
Second, temperature distribution at tumour surface 
was also recorded using an Infrared Camera (EasIR-2, 
Optophase, France) positioned 20 cm above the coil. 
For infrared measurements, temperatures were 
measured along the X axis (parallel to the coil axis) 
and Y axis (perpendicular to the coil axis). During 
hyperthermia treatment each mouse is positioned 
similarly inside the coil and the spatial temperature 
distribution in X and Y directions are determined 
from the hottest point detected by the infrared 
camera, which is always positioned 20 cm above the 
coil. With this set-up we minimize the variations in 
measurement conditions between mice. 
Specific absorption rates (SAR) of M-PLL and 
IONPs were measured in Watt per gram of iron, using 
the formula, SAR = Cv.(∆T/δt).1/CFe, where CV = 4.2 
J/(gK) is the specific heat capacity of water, ΔT/δt, 
measured in C° per second, are the initial slopes of 
temperature variation with time, and CFe, measured in 
g of iron per g (mL) of water, is the concentration of 
nanoparticles. SAR was measured at tumor centre in 
mice of groups 1 and 3 during first MS using 
temperature measurements with the optical fibre. For 
the value of CFe, we used the concentration of the 
administered IONPs and M-PLL suspension, 25 mg 
per mL of water, assuming that this corresponds to 25 
µg per mm3 of tumor. The method used for estimating 
the SAR in vivo is informative but would require 
further histological analysis to take into account in 
more details the nanoparticle distribution. In addition 
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to the SAR, maximum temperature reached in the 
tumor and full width half maximum of the 
temperature distribution are also measured to be able 
to compare the heating efficacy between IONPs and 
M-PLL. 
Statistics 
Mouse survival rates are plotted using the 
Kaplan-Meier model method. Statistical significance 
of survival rate between the different groups is 
evaluated using the log rank test. Parameters are 
expressed as median and as p-values, as compared 
with control group 6, [36]. 
Histological analysis 
For histological experiments, GL-261 
subcutaneous tumors were grown in female C57/BL6 
mice and treated under the same conditions than for 
thermotherapy treatments described above. Twelve 
mice were used for intratumoral injection of M-PLL 
(concentrations as above) in the presence (n=6) or not 
(n=6) of MS, 12 mice were used for intratumoral 
injection of IONPs (concentrations as above) in the 
presence (n=6) or not (n=6) of MS and 4 mice for the 
control conditions with glucose in the presence (n=2) 
or not (n=2) of MS. As before, MS included the 
application of a field of 10-32 mT and 198 kHz during 
30 minutes in order to maintain an intratumoral 
temperature between 43 and 46°C. Half of the mice of 
each group were euthanized 6 hours after 
nanoparticle injection (one MS, if applicable) and the 
remaining mice were killed 72 hours after 
nanoparticle injection i.e. 24 hours after the second MS 
(two MS, if applicable). For all mice, subcutaneous 
tumors or skin were dissected, fixed in 4 % 
paraformaldehyde and embedded in paraffin. 
Sections of 4 µm were cut and stained with 
hematoxylin-eosin (H&E) or Perls Prussian Blue. 
Sections were imaged using an automated slide 
scanner (lamina, Perkin Elmer, USA). 
Toxicity evaluation 
Nanoparticle pyrogenicity was evaluated firstly 
by measuring the endotoxin concentration of the 
different nanoparticles using the Limulus amebocyte 
lysate (LAL) tests (Pierce LAL Chromogenic 
Endotoxin Quantitation Kit, Thermo Fisher Scientific, 
USA) and secondly by the rabbit test according to 
ISO10993-11.  
Nanoparticle cytotoxicity was estimated for 
various nanoparticle and PLL concentrations (1000, 
500, 125, 62.5, 31.25 or 15.62 µg/mL) on 3T3 (mouse 
fibroblast) cells using an MTT assay according to ISO 
10993-5. Nanoparticles were considered as 
noncytotoxic for a percentage of cell inhibition below 
30%. Nanoparticle cytotoxicity was also assessed on 
GL-261 cells using an MTT assay, following the same 
protocol as that used for 3T3 cells.  
Nanoparticle acute systemic toxicity was 
evaluated according to ISO 10993-11. For that, 
C57/BL6 mice received 100 µL of M-PLL or IONPs (2 
or 4 mg) intravenously. During the 10 days following 
injection, potential acute toxicity was evaluated by 
monitoring mouse body weight and behaviour. 
More detailed information regarding 
nanoparticle toxicity evaluation is provided in the 
supplementary material section. 
Results and Discussion 
Categorization of M-PLL and IONPs 
M-PLL and IONPs were both categorized as 
medical devices of class III according to European 
regulation (2007/47/EC) since the main mechanism 
of tumor destruction using these nanoparticles 
exposed to AMF is due to heat, i.e. antitumor activity 
was not observed for nanoparticles administered to 
tumors without AMF application. ISO 10993 
international standards, which describe biological 
evaluation methods for medical devices that need to 
used according to drug agencies, were therefore 
followed.  
Properties of M-PLL 
Magnetosomes contained within whole 
magnetotactic bacteria, shown in Figure 1, or directly 
extracted from these bacteria without any specific 
treatments have been extensively studied due to their 
interesting properties such as high magnetization and 
chain arrangement, [37,38,39]. However, they cannot 
be used as such for biomedical application due to too 
high endotoxin concentrations, lying between 8.10+3 
and 1.10+5 EU/mL/mg, as measured with LAL test.  
We have therefore established a method for the 
fabrication of pyrogen-free magnetosomes that are 
biocompatible. For that, magnetosomes are first 
extracted from MSR-1 magnetotactic bacteria (Figures 
1a and 1b) and purified (Figures 1c and 1d) to remove 
potentially toxic uncharacterized organic and 
pyrogenic materials surrounding the magnetosome 
minerals, leading to suspensions of magnetosome 
minerals, designated as M, with endotoxin 
concentrations between 10 and 100 EU/mL/mg, 
comparable to that of 50 EU/mL/mg measured for 
IONPs yet derived from chemical synthesis and thus 
normally exempt of endotoxins, [40]. Endotoxins are 
mostly removed in these suspensions but a 
subsequent treatment is indeed necessary because M 
strongly aggregate. Indeed, absorbance measured at 
480 nm of a suspension containing M decreases by 
more than 80 % in 10 minutes (Figure S1). 
Furthermore, TEM images of M, presented in Figures 
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1c and 1d, show aggregated magnetosomes minerals. 
For medical applications, aggregation should be 
avoided since it prevents a thorough administration 
and can induce adverse effect such as embolism. 
To prevent their aggregation and enable their 
administration, M have therefore been coated with a 
polycationic polymer, PLL leading to M-PLL, [41]. 
TEM images of M-PLL, presented in Figures 1e and 1f, 
show a majority of coated magnetosomes of average 
sizes 40.5 ± 8.5 nm (Table S3 and Figure S2), with a 
majority organized in chains and a minority forming 
small aggregates. Composition of the magnetosome 
mineral core is determined to be maghemite using 
saturating isothermal remanent magnetization 
(Figure S3c), yielding saturating magnetization, Ms, 
and coercivity, Hc, values of 70 Am2/Kg and 6 mT, 
respectively (Table S3). The presence of a coating 
surrounding the core in M-PLL is first revealed by the 
TEM image of Figure 1f, which shows a coating layer 
of 4 to 17 nm thickness (Table S3). In addition to the 
peaks at 609 and 673 cm-1, due 
to iron oxide and also 
observed in the FT-IR 
spectrum of M (Figure S4a), 
the FT-IR spectrum of M-PLL 
(Figure S4a) reveals the 
presence of bands at 1546 cm-1 
and 1656 cm-1, which are 
attributed to NH and C=O 
compounds of amide funct-
ional groups contained in PLL, 
[42,43]. Second, CHNS 
analysis of M-PLL indicates 
4.9% of carbon and 1.1 % of 
nitrogen (Table S3), which are 
higher values than those 
measured for M, suggesting 
the presence of organic 
material in M-PLL (Figure 
S4c). Third, zeta potential of 
M-PLL is positive over a wider 
range of pH for M-PLL (2 < 
pH < 8) than for M (pH = 2) 
(Figure S4b), which is 
indicative of a positively 
charged material within the 
coating at the surface of 
M-PLL. Moreover, M-PLL 
suspensions are nonpyrogenic, 
i.e. their endotoxin conce-
ntration is 80 EU/mg/mL and 
they pass the rabbit test 
carried out according to ISO 
10993-11 (Supplementary 
Material). They are also 
considered as non-cytotoxic 
according to the criteria of ISO 
10993-5, (Supplementary 
Material and Figure S5), [44]. 
M-PLL in suspensions are also 
shown to be sufficiently stable 
to enable their administration 
since the absorbance of this 
suspension, measured at 480 
nm, decreases by less than 20 
 
 
Figure 1. TEM images of, (a), an intact MSR-1 magnetotactic bacterium with intracellular chains of magnetosomes, 
(b), enlargement of the bacterium shown in (a), (c), aggregated uncoated magnetosome minerals, (d), enlargement 
of (c), (e), magnetosome minerals coated with poly-L-lysine forming chains and small aggregates, (f), enlargement of 
(e) showing a chain of magnetosomes coated with poly-L-lysine, (g) dispersed IONPs. For these observations, 5 µl 
of suspensions containing whole bacteria, uncoated magnetosomes, magnetosome minerals coated with 
poly-L-lysine and IONPs are deposited and dried on a carbon grid and then observed by TEM. 
 
 Theranostics 2017, Vol. 7, Issue 18 
 
 
http://www.thno.org 
4624 
% in 15 minutes (Figure S1). Acute systemic toxicity of 
M-PLL, evaluated according to ISO 10993-11, by 
administering intravenously 100 µl of a M-PLL 
suspension of 25 or 50 mg of iron in M-PLL per ml in 
the tails of 6 weeks old C57/BL6 female mice indicate 
that the maximum tolerated dose (MTD) is larger than 
4 mg (Figure S6). This result agrees with a previous 
study, reporting low magnetosome acute toxicity with 
LD50 of 15 mg/kg in rats, [45]. Furthermore, MTD of 
M-PLL is sufficiently high to enable treatment since it 
is much above 0.5 g, the amount of nanoparticles 
currently administered to human glioma of 15 cm3 
treated with magnetic hyperthermia, [46,47].  
Properties of IONPs 
IONPs are composed of an iron oxide core 
surrounded by hydroxy-methyl-starch as confirmed 
by the FT-IR spectrum of IONPs that shows three 
dominant bands attributed on the one hand to iron 
oxide at 607 cm-1 and on the other hand to Starch 
polymer at 1022 cm-1 and 1150 cm-1 (Figure S4a). They 
have a rectangular shape, an average size of 17 ± 4 
(width) to 20 ± 5 (length) nm (Table S3), smaller than 
M-PLL, an organization in well dispersed small 
aggregates that differ from M-PLL chain arrangement, 
as observed in the TEM image of Figure 1g. This leads 
to Ms of 47 Am2/kg and to Hc of 11 mT in agreement 
with previously published data, [48]. Compared with 
M-PLL, they appear to be less positively charged, + 5 
mV at pH 7 (Figure S4b). They are stable in 
suspension (Figure S1) and biocompatible since they 
are nonpyrogenic, they are non-cytotoxic according to 
ISO 10993-5 (Figures S5a and S6) and characterized by 
a MTD larger than 4 mg.  
Comparison between in vivo distribution of 
M-PLL and IONPs following the different 
magnetic sessions, deduced from temperature 
measurements and histological analysis 
Previous studies have suggested to combine 
magnetic hyperthermia with MRI to determine iron 
oxide nanoparticle distribution in tumors during 
treatments, [49,50]. Under typical conditions 
applicable to magnetic hyperthermia treatment, i.e. 
following administration of 20 µl of magnetosomes at 
a concentration of 20 mg/mL at the center of 
intracranial RG-2 glioblastoma rat tumor of ~ 25 mm3 
and application of an AMF of 198 kHz and 20 mT for 
20 minutes, the MRI scan of the tumor (Figure S7) 
shows a dense dark area revealing the presence of 
concentrated magnetosomes. This indicates that 
magnetosomes, which are known to be efficient 
contrast agents, [51,52], can be imaged with MRI. 
However, from a clinical perspective, we are not 
certain that MRI could be used during the various 
magnetic sessions since a too large magnetosome 
concentration can hide the tumor, as observed in 
Figure S7, and an induction system generating an 
AMF can hardly be introduced in or combined with 
MRI since both equipments generate different 
magnetic fields. In fact, MRI may either be used 
before treatment to identify tumor location and 
possibly guide magnetosome injection or after 
treatment to follow tumor growth evolution or ensure 
that the tumor has disappeared. During the various 
magnetic sessions, although invasive a temperature 
measurement method such as that presented in this 
study seems more suitable than MRI to detect the 
presence of magnetosomes and determine their 
distribution. 
Nanoparticle temperature distribution is studied 
by administering 25 to 75 µl of a suspension 
containing M-PLL or IONPs at a concentration of 25 
µg of iron per mm3 of tumor once or twice at the 
centre of GL-261 glioma tumors of volumes of 50 to 
150 mm3 followed by 7 to 15 MS. We try to maintain 
intratumor temperature at 43-46 °C during the 
various MS by using, if necessary, a second 
intratumor nanoparticle administration and by 
adjusting the strength of the applied alternating 
magnetic field at 11 to 31 mT. Treatment parameters 
necessary to reach 43-46°C are used to compare 
nanoparticle and temperature distribution between 
M-PLL and IONPs.  
During the first MS, temperatures between 43 and 
46°C, measured 10 minutes following AMF 
application, are distributed within 3 mm (~ 100 mm3) 
surrounding the tumour for M-PLL (Figure 2c) 
compared with 2 mm (~ 30 mm3) for IONPs (Figure 
2d). From these observations, mild hyperthermia 
(between 43 and 46°C) occurs within 100% of the 
tumor volume for M-PLL compared with less than 
50% for IONPs (Figures 2c and 2d). We attribute these 
heating behaviors to higher heating capacity for 
M-PLL compared with IONPs. Indeed, the average 
SAR measured among 10 mice, deduced from the 
initial slopes of the temperature variations with time, 
∆T/δt = 0.2 °C/sec. and ∆T/δt = 0.15 °C/sec., and 
from CFe = 25 µg per mm3 of tumor, which is the 
estimated concentration of nanoparticles in the tumor, 
are 40 W/gFe and 26 W/gFe, for M-PLL and IONPs 
respectively (Figures 2a and 2b and Table S1). 
Moreover, the magnetic field strength necessary to 
reach 43-46°C is lower for M-PLL (11 to 27 mT) than 
for IONPs (22 to 31 mT). 
Concerning temperature measurements carried 
out during subsequent MS, it appears that the 
numbers of sessions, without nanoparticle 
re-administration, during which 50% of mice reached 
tumor temperatures of 43-46 °C are 3 and 1 for M-PLL 
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and IONPs, respectively, suggesting that the average 
time during which nanoparticles remain in sufficient 
quantity to heat the tumor is longer for M-PLL (5 
days) than for IONPs (1 day).  
While temperature, at 43-46 °C during the first 
MS, is distributed within a larger percentage of tumor 
volume for M-PLL than for IONPs, nanoparticle 
biodistribution, determined by optical microscopy 
analysis of tumor samples stained with H&E and 
Perls Prussian Blue reveals a very different behavior. 
Indeed, for samples collected 6 or 72 hours after 
nanoparticle administration without MS or followed 
by one or two MS, dense dark areas attributed to 
concentrated M-PLL are observed (Figures 3a, 3b, S8 
and S9). In striking contrast, for mice treated in the 
same conditions but receiving IONPs instead of 
M-PLL, IONPs are less aggregated than M-PLL and 
are more homogenously dispersed (Figures 5, S10 and 
S11). On the one hand, these behaviors suggest that 
the more homogenous temperature distribution 
observed with M-PLL is not due to more homogenous 
nanoparticle distribution, but instead to a higher SAR 
value for M-PLL than for IONPs. On the other hand, 
the fact that M-PLL heat the tumor for a longer period 
than IONPs may come from different cellular 
interaction properties between the two types of 
nanoparticles. Indeed, as observed in Figure 4c, 
IONPs are localized at the same position as cells 
suggesting that they are internalized in vivo, possibly 
leading to nanoparticle degradation, which can 
undermine their heating properties. Recent works 
have shown that, when IONPs are internalized into 
cells their heating properties are significantly lowered 
by 70 to 90 %, [53,54].  
 By contrast, as observed in Figure 3c, M-PLL are 
aggregated and seem to concentrate mainly between 
cells, which could better preserve their heating 
properties compared with IONPs. These differences 
in behaviour, observed between M-PLL and IONPs, 
could be attributed to differences in charge at tumor 
pH of 6 (24 mV for M-PLL compared with 7 mV for 
IONP), organization (chains containing more 6 
magnetosomes of size 40.5±8.5 nm for M-PLL versus 
single nanoparticle of average size 18.5±9 nm for 
IONPs), and magnetic properties (Ms ∼ 70 Am2/Kg 
for M-PLL compared with Ms ∼ 47 Am2/Kg for 
IONPs) as summarized in Table 
S3.  
Comparison between in 
vivo antitumor efficacy of 
M-PLL and IONPs 
suspensions administered 
to GL-261 subcutaneous 
glioma tumors exposed to 7 
to 15 MS  
To compare the antitumor 
efficacy of IONPs with that of 
M-PLL, 6 groups (n=10) are 
treated under the following 
conditions: mice receive 
intratumorally M-PLL followed 
by 11 to 15 MS (group 1) or 
without MS (group 2); mice 
receive intratumorally IONPs 
followed by 7 to 15 MS (group 
3) or without MS (group 4); 
mice are injected with glucose 
followed by 4 to 10 MS (group 
5) or without MS (group 6). 
 
Figure 2. Temperature increases, measured at tumor center with an optical fibre during the first MS for mice 
belonging to group 1, (a), or to group 3, (b). The error bar reflects temperature differences measured between 
the various mice. Spatial infrared temperature distribution, measured at the skin surface along the coil axis, X, or 
perpendicular to this axis, Y, with an infrared camera 10 minutes after the beginning of the first MS for mice 
belonging to group 1, (c), or for those belonging to group 3, (d). 
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Figure 3. (a), H&E and (b), Perls Prussian blue section of a subcutaneous 
GL-261 tumor (blue circles) injected with 25 µg in iron of M-PLL per mm3 of 
tumor and collected 6 hours after the first MS (M-PLL (6H) + AMF). (c), 
enlargement of (b). 
 
 
Figure 4. (a), H&E and (b), Perls Prussian blue section of a subcutaneous 
GL-261 tumor (blue circles) injected with 25 µg in iron of IONPs per mm3 of 
tumor and collected 6 hours after the first MS (IONPs (6H) + AMF). (c), 
enlargement of (b).  
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Figure 5. Tumor volume variation as a function of time following administration of glucose, M-PLL or IONPs for mice belonging to group 1, (a), group 2, (b), group 
3, (c), group 4, (d), group 5, (e), group 6, (f). Each mouse is designated by a number in each figure. 
 
 
 
Figure 6. Survival rate of mice belonging to group 1 (M-PLL+AMF), group 2 
(M-PLL-AMF), group 3 (IONPs+AMF), group 4 (IONPs-AMF), group 5 (Glucose 
(5%)+AMF), and group 6 (Glucose (5%)-AMF). 
Anti-tumor effects are strong for mice belonging 
to group 1. Indeed, Figure 5a shows that tumor fully 
disappears among 5 mice at D2 (M1), D25 (M2), D7 
(M5), D7 (M8) and D11 (M9) and that tumor growth is 
delayed among the remaining 5 mice (M3, M4, M6, 
M7, M10). Compared with control groups (groups 2, 5 
and 6), in which tumor volumes increase continuously 
without any sign of anti-tumor activity (Figures 5b, 5f 
and 5e), leading to median survival time of 10 to 15 
days, mice receiving M-PLL followed by 11 to 15 MS 
(group 1) are found to have much longer median 
survival times of 147 days (p<0.0001), (Figure 6 and 
Table S4). For a typical cured mouse without M-PLL 
re-administration (M8), photographs of tumors show 
that following 6 MS the tumor volume was 
considerably lower at day 11 (Figure 7b) than at day 0 
(Figure 7a) and that a crust had developed (Figures 
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7b). In this mouse, after 12 MS at day 25 the tumor has 
fully disappeared and a scar is observed at the initial 
tumor location (Figure 7c). At day 250, neither tumor 
regrowth nor scar is observed (Figure 7d). 
Furthermore, a histological section of skin collected at 
day 250 in the former tumor region shows the absence 
of tumor cells, of M-PLL or of any sign of fibrosis 
resulting from tissue regeneration (Figure 7e). To 
further examine the effect of the treatment on tissues 
surrounding the tumor, tissue is collected from and 
near a tumor having received M-PLL followed by two 
MS. In Figures S8e and S8f, few necrotic areas are 
observed outside of the tumor, essentially located in 
the surrounding skin, which is a sign of inflammation 
associated with the presence of a crust. No necrotic 
areas are observed in fatty or muscle tissues, 
suggesting that the treatment did not induce any 
significant damage to healthy tissues surrounding the 
tumor (Figure S9e). These observations indicate that 
treatment is very well tolerated generating no 
observable adverse effects. Furthermore, following 
treatments, M-PLL seem to be progressively removed 
from the initial tumor region. Indeed, at day 250, 
M-PLL are not observed in this region but instead 
inside macrophages in lymph nodes (Figure 8), 
suggesting M-PLL elimination by macrophages. In 
mice belonging to group 1, in which the M-PLL 
suspension was re-administered at day 11 (M10), D14 
(M3), D16 (M7) and D18 (M4), due to tumor volume 
exceeding 150% of initial tumor volume at day 0, a 
decrease in tumor volume is observed during the days 
following re-administration without leading to full 
tumor disappearance (Figure 5). It shows that 
nanoparticle re-administration can be used to 
re-induce antitumor activity when the latter cannot 
anymore be achieved by increasing the magnetic field 
strength.  
Anti-tumor activity is also observed among mice 
receiving IONPs followed by 7 to 15 MS (group 3) but 
is less pronounced. Indeed, tumor growth is delayed 
among 4 mice (M24, M26, M27, M29) and tumor 
disappears fully among 2 other mice at days 14 and 23 
(M28, M30) as shown in Figures 5c and Figure 6. 
Compared with group 1 treated by M-PLL 
administration followed by 11 to 15 MS, mice 
receiving IONPs followed by 7 to 15 MS are 
characterized by a much shorter median survival time 
of 24 days (p<0.0001) (Table S5).  
On the one hand, magnetic hyperthermia 
appears to be less safe with IONPs than with M-PLL 
since magnetic fields of higher strengths are required 
with IONPs (27 mT during first and subsequent MS) 
than with M-PLL (19 mT and 24 mT during first and 
subsequent MS, respectively) to yield anti-tumor 
efficacy. On the other hand, the longer residence time 
and the longer time at a temperature between 43-46 
°C, for M-PLL, may be attributed to more localized 
concentrated nanoparticles and to a higher SAR value. 
This leads to enhanced antitumor activity with 
M-PLL, possibly by promoting: i), vascular injury 
leading to tumor ischaemia, [55], ii), an immune 
response, possibly induced by activated stressed 
proteins such as heat shock proteins (HSP), [56, 57], 
iii), an apoptotic cell death mechanism, [58].  
Compared with previous preclinical studies 
showing increased survival by 15-44 days of rats 
bearing RG-2 or T-9 glioma tumors and treated by 
magnetic hyperthermia at 43-47 °C, [59,60], our study 
reports for the first-time full cure of subcutaneous 
GL-261 tumors in a significant percentage of mice 
(50%) using biocompatible nanoparticles synthesized 
biologically by magnetotactic bacteria with improved 
properties, compared with previously used 
chemically synthesized nanoparticles. 
Conclusion 
In summary, we present a method to fabricate 
pyrogen free biocompatible magnetosomes 
synthesized by magnetotatic bacteria. For that, 
magnetosomes are purified to remove bacterial 
residues and magnetosome minerals are stabilized 
with a poly-L-lysine coating to yield M-PLL. When 
M-PLL are administered to rats and mice, they are 
shown to be excellent MRI contrast agents, and to lead 
to 50% of mice fully cured 5 weeks following M-PLL 
administration and several applications of a safe 
AMF, i.e. characterized by H.f = 2-4 108 A.m-1.s-1, well 
below the threshold of 5.109 A.m−1.s−1 above which 
eddy currents may occur, [61]. Enhanced M-PLL 
efficacy compared with IONPs is attributed to a 
higher SAR value, i.e. SAR of 40 W/gFe and 26 W/gFe 
are estimated for M-PLL and IONP, respectively, and 
to a longer residence time in tumors, i.e. 5 and 1 day(s) 
for M-PLL and IONPs, respectively, which result in 
temperatures between 43 and 46 °C being more 
homogenously distributed within the whole tumor 
and being reached over a longer period of time 
without nanoparticle re-administration. Interestingly, 
improved M-PLL efficacy is obtained while tumor 
coverage is partial and nanoparticles are less 
dispersed. The mechanisms by which tumor without 
M-PLL or containing a low M-PLL quantity are 
destroyed upon application of an AMF may involve 
tumor ischemia and/or enhancement of the antitumor 
immune response.  
This study complements previous works, which 
showed that magnetosomes could be used in a range 
of different medical applications, (62), including 
diagnosis, (63), and cancer treatment, (64-67).  
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Figure 7. Photographs of a typical mouse following M-PLL injection belonging to group 1 showing, (a), a large tumor at D0, (b), a small tumor and a crust at D11, (c), 
the absence of tumor and a scar at D25 and (d), the absence of tumor and scar at D250. (e), H&E section of skin collected at D250 in region of initial tumor location 
showing the absence of tumor. 
 
Figure 8. H&E (a,b) and Perls Prussian blue (c,d) sections of a lymph node in the skin of a cured mice treated with 25 µg in iron of M-PLL per mm3 of tumor followed 
by 15 MS and collected at D250. (a), the whole lymph node. (b), an enlargement of (a) showing macrophages (black arrows). (c) and (d), enlargements of (a) showing 
blue coloration in the cytoplasm of macrophages (black arrows) suggesting the elimination of M-PLL from the region of initial tumor location by macrophages. 
 
Acknowledgments 
We would like to thank the Eurostars program 
(Nanoneck-2, E9309), subvention AIR from the region 
of Paris (A1401025Q) as well as the ANRT (CIFRE 
2013/0364 between Nanobacterie and 
palaeomagnetism laboratory at ‘’Institut de Physique du 
Globe de Paris’’, CIFRE 2014/0359 between 
Nanobacterie and the ‘’Muséum d’histoire naturelle’’), 
the ANR Méfisto. Raphaël Le Fèvre is a PhD student, 
working both at Nanobacterie and at the IPGP. Most 
of the experiments presented in this study, except 
magnetic measurements, were carried out in 
Nanobacterie Laboratory. Experiments were carried 
out by Raphaël Le Fèvre under general supervision of 
Edouard Alphandéry, with the help of Mickaël 
Durand-Dubief and Chalani Mandawala for 
nanoparticle preparation, Imène chebbi and Mickaël 
 Theranostics 2017, Vol. 7, Issue 18 
 
 
http://www.thno.org 
4630 
Durand-Dubief regarding in vitro and in vivo studies, 
Imène Chebbi, Caroline Maake, Clovis Adam, and the 
platform ‘Histim’ of the Cochin Institute concerning 
histological experiments. The writing of the article 
and analysis of the results were mainly carried out by 
Edouard Alphandéry and Raphael Le Fèvre, with the 
help of François Guyot, Caroline Maake, France 
Lagroix and Jean-Pierre Valet. Jean-Yves Delattre, 
Ahmed Idbaih, and Charlotte Schmitt commented on 
relevance of the preclinical protocol to verify that it is 
clinically applicable since this group will be possibly 
be in charge of the clinical trials using this treatment. 
Magnetic measurements were carried out at the IPGP 
under the supervision of France Lagroix and 
Jean-Pierre Valet.  
Other Information 
Mickaël Durand-Dubief carried out the work 
presented in this study while he was working at 
Nanobacterie. He is currently working at the 
department of Biosciences and Nutrition, Karolinska 
Institutet Novum, 141 83 Huddinge, Sweden and can 
be contacted at this address. 
Supplementary Material  
Supplementary figures and tables. 
http://www.thno.org/v07p4618s1.pdf  
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Figuerola A, Di Corato R, Manna L, Pellegrino T. From iron oxide 
nanoparticles towards advanced iron-based inorganic materials designed for 
biomedical applications. Pharmacol Res. 2010; 62(2): 126-43. 
2. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN. 
Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, 
physicochemical characterizations, and biological applications. Chem Rev. 
2008; 108(6): 2064-110. 
3. Kumar CS, Mohammad F. Magnetic nanomaterials for hyperthermia-based 
therapy and controlled drug delivery. Adv Drug Deliv Rev. 2011; 63(9): 
789-808. 
4. Bañobre-López M, Teijeiro A, Rivas J. Magnetic nanoparticle-based 
hyperthermia for cancer treatment. Rep Pract Oncol Radiother. 2013; 18(6): 
397-400. 
5. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, 
Budach V, Jordan A. Efficacy and safety of intratumoral thermotherapy using 
magnetic iron-oxide nanoparticles combined with external beam radiotherapy 
on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011; 
103(2): 317-24. 
6. Hanihara M, Kawataki T, Oh-Oka K, Mitsuka K, Nakao A, Kinouchi H. 
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and 
temozolomide in a murine glioma model. J Neurosurg. 2016; 124(6): 1594-601. 
7. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert 
MR, Black PM, Loeffler JS. Temozolomide-mediated radiation enhancement in 
glioblastoma: a report on underlying mechanisms. Clin Cancer Res. 2006; 
12(15): 4738-46. 
8. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, 
Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, 
Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, 
Mirimanoff RO; European Organisation for Research and Treatment of Cancer 
Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada 
Clinical Trials Group. Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-96. 
9. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, 
Purow BW, Borkowf CB. Phase II trial of thalidomide and carmustine for 
patients with recurrent high-grade gliomas. J Clin Oncol. 2003; 21(12): 
2299-304. 
10. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, 
Richardson P. Thalidomide- and lenalidomide-associated thromboembolism 
among patients with cancer. JAMA. 2006; 296(21): 2558-60. 
11. Authier A, Farrand KJ, Broadley KW, Ancelet LR, Hunn MK, Stone S, 
McConnell MJ, Hermans IF. Enhanced immunosuppression by 
therapy-exposed glioblastoma multiforme tumor cells. Int J Cancer. 2015; 
136(11): 2566-78. 
12. Matsunaga T, Suzuki T, Tanaka M, Arakaki A. Molecular analysis of 
magnetotactic bacteria and development of functional bacterial magnetic 
particles for nano-biotechnology. Trends Biotechnol. 2007; 25(4): 182-8. 
13. Araujo AC, Abreu F, Tavares Silva K, Bazylinski D, Lins U. Magnetotactic 
Bacteria as Potential Sources of Bioproducts. Mar Drugs. 2015; 13(1): 389–430. 
14. Orlando T, Mannucci S, Fantechi E, Conti G, Tambalo S, Busato A, Innocenti C, 
Ghin L, Bassi R, Arosio P, Orsini F, Sangregorio C, Corti M, Casula MF, 
Marzola P, Lascialfari A, Sbarbati A. Characterization of magnetic 
nanoparticles from Magnetospirillum Gryphiswaldense as potential 
theranostics tools. Contrast Media Mol Imaging. 2016; 11(2): 139-45. 
15. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of 
functionalized magnetic nanoparticles. J Biosci Bioeng. 2005; 100(1): 1-11. 
16. Alphandéry E, Faure S, Seksek O, Guyot F, Chebbi I. Chains of magnetosomes 
extracted from AMB-1 magnetotactic bacteria for application in alternative 
magnetic field cancer therapy. ACS Nano. 2011; 5(8): 6279-96.  
17. Alphandéry E, Amor M, Guyot F, Chebbi I. The effect of iron-chelating agents 
on Magnetospirillum magneticum strain AMB-1: stimulated growth and 
magnetosome production and improved magnetosome heating properties. 
Appl Microbiol Biotechnol. 2012; 96(3): 663-70. 
18. Matsunaga T, Tadokoro F, Nakamura N. Mass culture of magnetic bacteria 
and their application to flow type immunoassays. IEEE Transactions on 
Magnetics. 1990; 26(5): 1557-59. 
19. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. 
Intracellular hyperthermia for cancer using magnetite cationic liposomes: an 
in vivo study. Jpn J Cancer Res. 1998; 89(4): 463-9. 
20. Suzuki M, Shinkai M, Honda H, Kobayashi T. Anticancer effect and immune 
induction by hyperthermia of malignant melanoma using magnetite cationic 
liposomes. Melanoma Res. 2003; 13(2): 129-35. 
21. Tanaka K, Ito A, Kobayashi T, Kawamura T, Shimada S, Matsumoto K, Saida 
T, Honda H. Heat immunotherapy using magnetic nanoparticles and 
dendritic cells for T-lymphoma. J Biosci Bioeng. 2005; 100(1): 112-5. 
22. Johannsen M, Thiesen B, Gneveckow U, Taymoorian K, Waldöfner N, Scholz 
R, Deger S, Jung K, Loening SA, Jordan A. Thermotherapy using magnetic 
nanoparticles combined with external radiation in an orthotopic rat model of 
prostate cancer. Prostate. 2006; 66(1): 97-104. 
23. Toraya-Brown S, Sheen MR, Zhang P, Chen L, Baird JR, Demidenko E, Turk 
MJ, Hoopes PJ, Conejo-Garcia JR, Fiering S. Local hyperthermia treatment of 
tumors induces CD8 (+) T cell-mediated resistance against distal and 
secondary tumors. Nanomedicine. 2014; 10(6): 1273-85. 
24. Zadnik PL, Molina CA, Sarabia-Estrada R, Groves ML, Wabler M, Mihalic J, 
McCarthy EF, Gokaslan ZL, Ivkov R, Sciubba D. Characterization of 
intratumor magnetic nanoparticle distribution and heating in a rat model of 
metastatic spine disease. J Neurosurg Spine. 2014; 20(6): 740-50. 
25. Dennis CL, Jackson AJ, Borchers JA, Hoopes PJ, Strawbridge R, Foreman AR, 
van Lierop J, Grüttner C, Ivkov R. Nearly complete regression of tumors via 
collective behavior of magnetic nanoparticles in hyperthermia. 
Nanotechnology. 2009; 20(39): 395103. 
26. Schultheiss D, Schüler D. Development of a genetic system for 
Magnetospirillum gryphiswaldense. Arch Microbiol. 2003; 179(2): 89-94. 
27. Heyen U, Schüler D. Growth and magnetosome formation by microaerophilic 
Magnetospirillum strains in an oxygen-controlled fermentor. Appl Microbiol 
Biotechnol. 2003; 61(5-6): 536-44. 
28. Zhang Y, Zhang X, Jiang W, Li Y, Li J. Semicontinuous culture of 
Magnetospirillum gryphiswaldense MSR-1 cells in an autofermentor by 
nutrient-balanced and isosmotic feeding strategies. Appl Environ Microbiol. 
2011; 77(17): 5851-6.  
29. Yang J, Li S, Huang X, Tang T, Jiang W, Zhang T, Li Y. A key time point for cell 
growth and magnetosome synthesis of Magnetospirillum gryphiswaldense 
based on real-time analysis of physiological factors. Front Microbiol. 2013; 4: 
210. 
30. Sun JB, Zhao F, Tang T, Jiang W, Tian JS, Li Y, Li JL. High-yield growth and 
magnetosome formation by Magnetospirillum gryphiswaldense MSR-1 in an 
oxygen-controlled fermentor supplied solely with air. Appl Microbiol 
Biotechnol. 2008; 79(3): 389-97. 
31. Bordelon DE, Cornejo C, Grüttner C, Westphal F, DeWeese TL, Ivkov R. 
Magnetic nanoparticle heating efficiency reveals magneto-structural 
differences when characterized with wide ranging and high amplitude 
alternating magnetic fields. J. Appl. Phys. 2011; 109:124904. 
32. Kekalo K, Baker I, Meyers R, Shyong J. Magnetic Nanoparticles with High 
Specific Absorption Rate at Low Alternating Magnetic Field. Nano Life. 2015; 
5(2): 1550002. 
33. Patent/US20150306246A1. Magnetic nanoparticles, composites, suspensions 
and colloids with high specific absorption rate (sar). Issued 6 December 2013. 
34. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in 
athymic (nude) mice. Cancer Chemother Pharmacol. 1989; 24(3): 148-54.  
 Theranostics 2017, Vol. 7, Issue 18 
 
 
http://www.thno.org 
4631 
35. Ito A, Shinkai M, Honda H, Kobayashi T. Heat-inducible TNF-alpha gene 
therapy combined with hyperthermia using magnetic nanoparticles as a novel 
tumor targeted therapy. Cancer Gene Ther. 2001; 8(9): 649-54. 
36. Heitjan DF, Manni A, Santen RJ. Statistical analysis of in vivo tumor growth 
experiments. Cancer Res. 1993; 53(24): 6042-50. 
37. Lang C, Schüler D, Faivre D. Synthesis of magnetite nanoparticles for bio- and 
nanotechnology: genetic engineering and biomimetics of bacterial 
magnetosomes. Macromol Biosci. 2007; 7(2): 144-51. 
38. Yan L, Zhang S, Chen P, Liu H, Yin H, Li H. Magnetotactic bacteria, 
magnetosomes and their application. Microbiol Res. 2012; 167(9): 507-19. 
39. Staniland SS. Magnetosomes: Bacterial biosynthesis of magnetic nanoparticles 
and potential biomedical applications. In: Wiley-VCH. Magnetic 
nanomaterials. 2009: 399-430.  
40. Andrade SS, Silveira RL, Schmidt C, Dalmora SL. Comparative evaluation of 
the human whole blood and human peripheral blood monocyte tests for 
pyrogens. International Journal of Pharmaceutics. 2004; 265(1-2): 115-24. 
41. Wang X, Wei F, Liu A, Wang L, Wang JC, Ren L, Liu W, Tu Q, Li L, Wang J. 
Cancer stem cell labeling using poly (L-lysine)-modified iron oxide 
nanoparticles. Biomaterials. 2012; 33(14): 3719-32. 
42. Rozenberg M, Shoham G. FTIR spectra of solid poly-l-lysine in the stretching 
NH mode range. Biophys Chem. 2007; 125(1): 166-71. 
43. Tam SK, Dusseault J, Polizu S, Ménard M, Hallé JP, Yahia L. Physicochemical 
model of alginate-poly-L-lysine microcapsules defined at the 
micrometric/nanometric scale using ATR-FTIR, XPS, and ToF-SIMS. 
Biomaterials. 2005; 26(34): 6950-61. 
44. ISO 10993-12:2007 - Biological Evaluation of Medical Devices -- Part 12: 
Sample Preparation and Reference Materials, ISO, accessed 21 November 
2016. 
45. Isaksson K, Akerberg D, Posaric-Bauden M, Andersson R, Tingstedt B. In vivo 
toxicity and biodistribution of intraperitoneal and intravenous poly-L-lysine 
and poly-L-lysine/poly-L-glutamate in rats. J Mater Sci Mater Med. 2014; 
25(5): 1293-9. 
46. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative 
comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, 
monkey, and man. Cancer Chemother Rep. 1966; 50(4): 219-44.  
47. Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, Feussner 
A, von Deimling A, Waldoefner N, Felix R, Jordan A. Intracranial 
thermotherapy using magnetic nanoparticles combined with external beam 
radiotherapy: results of a feasibility study on patients with glioblastoma 
multiforme. J Neurooncol. 2007; 81(1): 53-60. 
48. Branquinho LC, Carrião MS, Costa AS, Zufelato N, Sousa MH, Miotto R, Ivkov 
R, Bakuzis AF. Effect of magnetic dipolar interactions on nanoparticle heating 
efficiency: implications for cancer hyperthermia. Sci Rep. 2013; 3: 2887. 
49. Hayashi K, Nakamura M, Sakamoto W, Yogo T, Miki H, Ozaki S, Abe M, 
Matsumoto T, Ishimura K. Superparamagnetic nanoparticle clusters for cancer 
theranostics combining magnetic resonance imaging and hyperthermia 
treatment. Theranostics. 2013; 3(6): 366-76. 
50. Zhao Q, Wang L, Cheng R, Mao L, Arnold RD, Howerth EW, Chen ZG, Platt S. 
Magnetic nanoparticle-based hyperthermia for head & neck cancer in mouse 
models. Theranostics. 2012; 2: 113-21. 
51. Hu L ; Zhang F, Wang F, You XF, Nie L, Wang HX, Song T, Yang WH. 
Comparison of the 1H NMR Relaxation Enhancement Produced by Bacterial 
Magnetosomes and Synthetic Iron Oxide Nanoparticles for Potential Use as 
MR Molecular Probes. IEEE Transactions on Applied Superconductivity. 2011; 
20(3): 822-825. 
52. Lee N, Kim H, Choi SH, Park M, Kim D, Kim HC, Choi Y, Lin S, Kim BH, Jung 
HS, Kim H, Park KS, Moon WK, Hyeon T. Magnetosome-like ferrimagnetic 
iron oxide nanocubes for highly sensitive MRI of single cells and transplanted 
pancreatic islets. PNAS. 2011; 108(7): 2662-7. 
53. Di Corato R, Espinosa A, Lartigue L, Tharaud M, Chat S, Pellegrino T, 
Ménager C, Gazeau F, Wilhelm C. Magnetic hyperthermia efficiency in the 
cellular environment for different nanoparticle designs. Biomaterials. 2014; 
35(24): 6400-11. 
54. Guardia P, Di Corato R, Lartigue L, Wilhelm C, Espinosa A, Garcia-Hernandez 
M, Gazeau F, Manna L, Pellegrino T. Water-soluble iron oxide nanocubes with 
high values of specific absorption rate for cancer cell hyperthermia treatment. 
ACS Nano. 2012; 6(4): 3080-91. 
55. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and 
advances in therapy. Nat Rev Cancer. 2014; 14(3): 199-208. 
56. Toraya-Brown S, Fiering S. Local tumour hyperthermia as immunotherapy for 
metastatic cancer. Int J Hyperthermia. 2014; 30(8): 531–539. 
57. Ito A, Shinkai M, Honda H, Yoshikawa K, Saga S, Wakabayashi T, Yoshida J, 
Kobayashi T. Heat shock protein 70 expression induces antitumor immunity 
during intracellular hyperthermia using magnetite nanoparticles. Cancer 
Immunol Immunother. 2003; 52(2): 80-8. 
58. Hall EJ. The bystander effect. Health Phys. 2003; 85(1): 31-5. 
59. Jordan A, Scholz R, Maier-Hauff K, van Landeghem FK, Waldoefner N, 
Teichgraeber U, Pinkernelle J, Bruhn H, Neumann F, Thiesen B, von Deimling 
A, Felix R. The effect of thermotherapy using magnetic nanoparticles on rat 
malignant glioma. J Neurooncol. 2006; 78(1): 7-14. 
60. Ohno T, Wakabayashi T, Takemura A, Yoshida J, Ito A, Shinkai M, Honda H, 
Kobayashi T. Effective solitary hyperthermia treatment of malignant glioma 
using stick type CMC-magnetite. In vivo study. J Neurooncol. 2002; 56(3): 
233-9. 
61. Dutz S, Hergt R. Magnetic nanoparticle heating and heat transfer on a 
microscale: Basic principles, realities and physical limitations of hyperthermia 
for tumour therapy. Int J Hyperthermia. 2013; 29(8): 790-800. 
62. Alphandéry E, Grand-Dewyse P, Le Fèvre R, Mandawala C, Durand-Dubief 
M. Cancer therapy using nanoformulated substances: scientific, regulatory 
and financial aspects. Expert Review of anticancer therapy. 2015; 15(10): 
1233-1255. 
63. Alphandéry E, Lijeour L, Lalatonne Y, Motte L. Different signatures between 
chemically and biologically synthesized nanoparticles in a magnetic sensor: A 
new technology for multiparametric detection. Sensors and Actuators B. 2010; 
147: 786-790. 
64. Alphandéry E, Idbaih A, Adam C, Delattre J-Y, Schmitt C, Guyot F, Chebbi I. 
Chains of magnetosomes with controlled endotoxin release and partial tumor 
occupation induce full tumor destruction of intracranial U87-Luc glioma in 
mice under the application of an alternating magnetic field. Journal of 
controlled release. 2017; 262: 259-272. 
65. Alphandéry E, Idbaih A, Adam C, Delattre J-Y, Schmitt C, Guyot F, Chebbi I. 
Development of non-pyrogenic magnetosome minerals coated with 
poly-l-lysine leading to full disappearance of incranial U87-Luc glioblastoma 
in 100% of treated mice using magnetic hyperthermia. Biomaterials. 2017; 141: 
210-222. 
66. Mandawala C, Chebbi I, Durand-Dubief M, Le Fèvre R, Hamdous Y, Guyot F, 
Alphandéry E. Biocompatible and stable magnetosome minerals coated with 
poly-l-lysine, citric acid, and carboxy-methyl-dextran for application in the 
magnetic hyperthermia treatment of tumors. Journal of Materials Chemistry B. 
2017. DOI: 10.1039/c6tb03248f 
67. Hamdous Y, Chebbi I, Mandawala C, Le Fèvre R, Guyot F, Seksek O, 
Alphandéry E. Biocompatible coated magnetosome minerals with various 
organization and cellular interaction properties induce cytotoxicity towards 
RG-2 and GL-261 glioma cells in the presence of an alternating magnetic field. 
Journal of nanobiotchnlogy. 2017. DOI: 10.1186/s12951-017-0293-2. 
 
